# US Preclinical Imaging Market > US Preclinical Imaging Market Research Report: Size, Share, Trend Analysis By Product (Optical Imaging, Nuclear Imaging, Micro-MRI, Micro-Ultrasound, Micro-CT, Photoacoustic Imaging System) and By Distribution Channel (Optical, Nuclear, CT Contrast Agents, MRI Contrast Agents) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.9% - **2024:** $ 1,043.7 Million - **2025:** $ 1,105.28 Million - **2035:** $ 1,961.2 Million - **Key Players:** Bruker Corporation (US), PerkinElmer Inc. (US), Siemens Healthineers (DE), GE Healthcare (US), Fujifilm Holdings Corporation (JP), Miltenyi Biotec (DE), Thermo Fisher Scientific Inc. (US), Invicro LLC (US), Mediso Medical Imaging Systems (HU) **Report ID:** MRFR/MED/11681-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-preclinical-imaging-market-13206 --- ## Market Summary ## **US Preclinical Imaging Market Overview** As per MRFR analysis, the US Preclinical Imaging Market Size was estimated at 0.97 (USD Billion) in 2023. The US Preclinical Imaging Market Industry is expected to grow from 1.04(USD Billion) in 2024 to 2.08 (USD Billion) by 2035. The US Preclinical Imaging Market CAGR (growth rate) is expected to be around 6.458% during the forecast period (2025 - 2035). ### **Key Market Trends of US Preclinical Imaging Market Highlighted** The US Preclinical Imaging Market is currently experiencing significant growth, driven by technological advancements and an increase in funding for research and development activities. The rise of personalized medicine has heightened the need for better preclinical imaging solutions, as researchers aim to gain deeper insights into disease mechanisms and test new therapies more efficiently. With institutions like the National Institutes of Health advocating for more comprehensive research methodologies, the demand for state-of-the-art imaging technologies such as MRI, PET, and SPECT continues to expand. Opportunities in the US market include collaborations between academic institutions and private companies, leading to innovative imaging techniques and enhanced data analysis methods. Such partnerships are crucial in overcoming challenges related to complex disease modeling and translating findings from animal models to human applications. The increasing focus on non-invasive imaging technologies also presents a chance for market participants to enhance their offerings and capture a broader customer base. In recent times, trends suggest a surge in utilizing advanced imaging modalities that offer high-resolution and multi-modality features. This allows researchers to obtain more precise data, thereby accelerating drug discovery processes. Moreover, the integration of artificial intelligence in image analysis is becoming commonplace, facilitating faster and more accurate interpretations of imaging data. US institutions are embracing these innovations, as funding and grants for advanced imaging research have seen a notable increase. Overall, the confluence of technological advancements, research funding, and shifting market dynamics is shaping the landscape of the US [preclinical imaging](../../../reports/preclinical-imaging-market-7365) market in a significant way. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Preclinical Imaging Market Drivers** ### **Growing Demand for Advanced Imaging Techniques** The US Preclinical Imaging Market Industry is experiencing significant growth driven by the increasing demand for advanced imaging techniques to support Research and Development in various fields such as pharmacology and toxicology. According to the United States National Institutes of Health, over 60% of research institutions have reported an increase in funding for imaging technologies, with projected budgets growing due to the necessity for improved imaging methods that provide superior resolution and accuracy in animal models. This trend reflects the commitment of major organizations, such as the American Association for Laboratory Animal Science, which emphasizes the need for enhanced imaging capabilities in preclinical studies. The growth in imaging technologies is projected to push more researchers toward adopting these advanced methodologies, directly impacting the US Preclinical Imaging Market and leading to innovations and developments in per-existing imaging modalities. ### **Increase in Chronic Diseases and R&D Investment** The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions in the United States, is a significant driver for the US Preclinical Imaging Market Industry. The Centers for Disease Control and Prevention reports that around 6 in 10 adults in the US have a chronic disease, highlighting the urgent need for better diagnostic and therapeutic imaging solutions. With pharmaceutical companies investing significantly in Research and Development, approximately 20% of their revenue is accounted for in R&D, fostering advancements in imaging technologies to support preclinical testing. Such expansions in R&D budgets align with the critical need for effective imaging for accurate disease modeling and biomarker identification, fueling growth within the preclinical imaging segment. ### **Technological Advancements in Imaging Modalities** Technological innovations are driving the growth of the US Preclinical Imaging Market Industry as organizations continue to adopt and develop novel imaging modalities. Enhanced technologies such as positron emission tomography-computed tomography (PET-CT), magnetic resonance imaging (MRI), and optical imaging are becoming commonplace in preclinical settings. Research from the National Institutes of Health indicates that new imaging systems are consistently outperforming traditional methods, increasing the accuracy of drug efficacy studies and minimizing the need for animal testing. Furthermore, expertise from established companies, such as Bruker Corporation and PerkinElmer, is pivotal in developing cutting-edge imaging technologies. The sustained investment by these companies in technological developments further solidifies a competitive edge in the market, which is expected to yield a substantial increase in the adoption of advanced imaging techniques. ## **US Preclinical Imaging Market Segment Insights** ### **Preclinical Imaging Market Product Insights** The US Preclinical Imaging Market is a crucial component of biomedical research, providing vital insights that propel advancements in medical technology and innovation. One of the key Product segments in this market is Optical Imaging, which utilizes various techniques to allow researchers to visualize biological processes at the cellular and molecular levels. This technology, known for its non-invasive nature, enables real-time monitoring of disease progression and therapeutic responses, thereby fostering accelerated drug development and Research and Development initiatives. Additionally, Nuclear Imaging plays a significant role, employing radioisotopes to produce detailed images of the metabolic activity within living organisms. This technique is invaluable for tracking disease processes at early stages and evaluating the efficacy of new treatments. Micro-MRI represents another important aspect of the market, allowing for high-resolution imaging of small animal models, which is critical in understanding disease mechanisms and the development of new therapies. This modality provides comparable insights to clinical MRI while catering specifically to preclinical research needs, thereby enhancing the value of experimental findings. In parallel, Micro-Ultrasound is gaining attention due to its ability to provide real-time imaging with minimal invasiveness, making it a favorable tool for tracking angiogenesis and tissue development in various research contexts. Moreover, Micro-CT is significant for its detailed anatomical visualization, which aids researchers in accessing precise information regarding the structure and function of small animals. This technique is often employed in studies involving drug efficacy and safety assessments, which aligns closely with regulatory guidance for preclinical evaluations. Lastly, the Photoacoustic Imaging System demonstrates a unique capability to combine the benefits of optical and ultrasound imaging, allowing for the study of various biological phenomena in real time with enhanced imaging contrast. Together, these diverse modalities represent a comprehensive Product segment of the US Preclinical Imaging Market, each contributing uniquely to advancements in medical research. The interplay of different imaging techniques equips researchers with a rich toolkit to tackle complex biological questions, thereby fueling innovation and enhancing the pace of discovery in biomedical fields. As the market evolves, the synergy among these imaging strategies will further underscore their significance in driving forward the landscape of medical research in the US. The continuous improvement in imaging technologies is expected to facilitate new opportunities for growth and address the rising demands in the field. Overall, the US Preclinical Imaging Market stands as a vital player in the advancement of healthcare solutions, driven by a strong foundation in innovative imaging products. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Preclinical Imaging Market Distribution Channel Insights** The US Preclinical Imaging Market reveals diverse avenues through its Distribution Channel segment, which encompasses various modalities such as Optical, Nuclear, CT Contrast Agents, and MRI Contrast Agents. Each of these components plays a vital role in advancing the detection and analysis of biological processes. Optical imaging emerged as an accessible tool for visualizing cellular activities, making it significant in Research and Development for drug discovery and genetic studies. Meanwhile, Nuclear imaging techniques stand out for their ability to provide precise functional information, thereby dominating many preclinical applications. CT Contrast Agents play a critical role in enhancing image quality and ensuring accurate diagnostics, making them indispensable in preclinical trials. MRI Contrast Agents are notable for their high-resolution imaging capabilities, allowing researchers to investigate intricate anatomical structures and functionalities. The interplay among these distribution channels underpins the growth dynamics of the US Preclinical Imaging Market, driven by increased funding from the US government for biomedical research and the rising emphasis on the development of advanced imaging technologies within research institutions and laboratories. ## **US Preclinical Imaging Market Key Players and Competitive Insights** The US Preclinical Imaging Market is an ever-evolving landscape characterized by advanced technologies and innovations aimed at enhancing biomedical research. The competitive dynamics within this market are fueled by an increasing demand for effective preclinical imaging solutions that provide critical insights into the biological processes of diseases. The market is driven by factors such as rising investments in life sciences research, the pursuit of novel therapeutic approaches, and regulatory support that encourages the development of cutting-edge imaging modalities. Various players within the market are strategically positioning themselves by offering a diverse range of imaging technologies, such as magnetic resonance imaging, optical imaging, and nuclear imaging systems. This competitive ecosystem fosters innovation while providing researchers with essential tools to push the boundaries of preclinical study. ### **Mediso** Mediso has established a notable presence in the US Preclinical Imaging Market, recognized for its high-quality imaging systems designed for various applications in life sciences. The company focuses on providing advanced imaging solutions that enhance research capabilities in pharmacology, oncology, and neurology. Known for its commitment to technological advancement, Mediso offers products characterized by a significant level of precision and speed. Furthermore, its strong customer support and tailored service offerings add to its competitive edge in the US market, making it a preferred choice among research institutions and pharmaceutical companies. The company’s relentless innovation is coupled with partnerships with leading research organizations, which further solidifies its reputation and positioning in a competitive landscape. ### **Bruker** Bruker, another key player in the US Preclinical Imaging Market, offers a comprehensive portfolio of preclinical imaging technologies that cater to a wide array of research needs. The company is recognized for its sophisticated imaging modalities, including magnetic resonance imaging, fluorescence imaging, and multi-modal imaging systems. Bruker's strengths lie in its deep integration of imaging technologies with powerful analytical capabilities, enabling researchers to extract meaningful data from their studies efficiently. The presence of Bruker in the US market is robust, reinforced by strategic mergers and acquisitions that have expanded its product offerings and market reach. In addition to high-quality imaging systems, Bruker emphasizes collaborations with academic and research institutions, which further enhances its credibility and market presence. This multifaceted approach ensures that Bruker maintains a competitive advantage, by providing innovative solutions that meet the evolving demands of preclinical research in the US. ### **Key Companies** ## **US Preclinical Imaging Market Industry Developments** Recent developments in the US Preclinical Imaging Market have indicated significant advancements and investments in imaging technologies. Companies such as Mediso and Bruker have made strides in enhancing imaging resolutions and capabilities through the development of next-generation imaging systems. PerkinElmer and Thermo Fisher Scientific have also focused on expanding their product portfolios to integrate advanced image analysis software with imaging systems, optimizing research efficiencies. In terms of mergers and acquisitions, a notable transaction occurred in August 2023 when GE Healthcare acquired a leading imaging technology firm, further consolidating its position in the preclinical imaging market. Additionally, Siemens Healthineers has been expanding its portfolio through strategic partnerships aimed at innovating imaging solutions for preclinical research. The growth in valuation for companies within this market segment reflects increasing demand for advanced imaging techniques, facilitating better research outcomes in fields such as drug discovery and development. Over the past few years, significant investments in Research and Development within this sector have propelled advancements in imaging technologies, showcasing an upward trend in market dynamics. ## **US Preclinical Imaging Market Segmentation Insights** ### **Preclinical Imaging Market Product Outlook** ### **Preclinical Imaging Market Distribution Channel Outlook** - Optical - Nuclear - CT Contrast Agents - MRI Contrast Agents ## Market Drivers ### Expansion of Research Funding In the United States, the preclinical imaging market is benefiting from an expansion in research funding. Government agencies and private organizations are increasingly investing in biomedical research, which includes preclinical studies that utilize advanced imaging technologies. For instance, the National Institutes of Health (NIH) has allocated substantial grants to projects that incorporate imaging techniques to enhance drug discovery and development. This influx of funding is likely to stimulate innovation and adoption of new imaging technologies, thereby propelling the growth of the preclinical imaging market. As funding continues to rise, it is expected that the market will see an influx of new players and technologies. ### Technological Integration and Innovation The preclinical imaging market is characterized by ongoing technological integration and innovation. Advances in imaging technologies, such as the development of hybrid imaging systems that combine modalities like PET/CT and MRI, are enhancing the capabilities of researchers. These innovations allow for more comprehensive data collection and analysis, which is crucial for preclinical studies. The integration of artificial intelligence and machine learning into imaging analysis is also emerging, potentially improving the accuracy and efficiency of data interpretation. As these technologies continue to evolve, they are likely to drive the growth of the preclinical imaging market, offering researchers new tools to advance their studies. ### Growing Applications in Oncology Research The preclinical imaging market is witnessing a surge in applications within oncology research. As cancer remains a leading cause of mortality, there is an urgent need for effective diagnostic and therapeutic strategies. Imaging technologies such as bioluminescence and fluorescence are being increasingly utilized to monitor tumor growth and response to treatment in preclinical models. This trend is supported by the increasing number of oncology-focused research initiatives, which are projected to drive the market's growth. The oncology segment is expected to account for a significant share of the preclinical imaging market, reflecting the critical role of imaging in advancing cancer research. ### Rising Demand for Non-Invasive Techniques The preclinical imaging market is experiencing a notable increase in demand for non-invasive imaging techniques. Researchers and pharmaceutical companies are increasingly prioritizing methods that minimize harm to animal subjects while providing accurate data. This shift is driven by ethical considerations and regulatory pressures, as well as the need for reliable data in drug development. The market for non-invasive imaging modalities, such as MRI and PET, is projected to grow significantly, with estimates suggesting a CAGR of around 8% over the next few years. This trend indicates a robust future for the preclinical imaging market, as it aligns with the broader movement towards humane research practices. ### Increased Collaboration Between Academia and Industry The preclinical imaging market is benefiting from increased collaboration between academic institutions and industry players. Partnerships are forming to leverage academic research capabilities alongside industry resources, facilitating the development of innovative imaging solutions. These collaborations often result in the sharing of knowledge, technology, and funding, which can accelerate the pace of research and development. As more academic institutions engage with industry partners, the preclinical imaging market is expected to expand, fostering an environment conducive to innovation and the introduction of new imaging modalities. ## Future Outlook The [Preclinical Imaging Market](https://www.marketresearchfuture.com/reports/preclinical-imaging-market-7365) is projected to grow at a 5.9% CAGR from 2025 to 2035, driven by technological advancements and increasing R&D investments. **New opportunities:** - Development of AI-driven imaging software solutions - - Expansion of imaging services in contract research organizations - Integration of multimodal imaging systems for enhanced diagnostics By 2035, the market is expected to achieve substantial growth, reflecting evolving research needs. ## Segment Insights ### By Product: Optical Imaging (Largest) vs. Nuclear Imaging (Fastest-Growing) In the US preclinical imaging market, Optical Imaging holds a significant share, making it the largest segment within the product category. This segment is widely utilized due to its ability to provide real-time insights into biological processes, making it favorable for a range of applications. In contrast, Nuclear Imaging, while holding a smaller share currently, is recognized for its rapid growth trajectory as advancements in technology enhance its capabilities and applications in preclinical studies. The growth trends of these segments are driven by increased investments in research and development, and the rise in demand for innovative imaging technologies to improve the efficiency of preclinical studies. Optical Imaging continues to dominate due to its accessibility and effectiveness, while Nuclear Imaging is projected to rise significantly thanks to new integrations with AI and improved imaging techniques. These advancements foster a competitive environment where both segments can thrive under distinct applications and market conditions. Optical Imaging (Dominant) vs. Micro-MRI (Emerging) Optical Imaging is currently the dominant force in the US preclinical imaging market, renowned for its non-invasive nature that allows for real-time imaging of living subjects. This segment utilizes various technologies, including fluorescent and bioluminescent imaging, enabling researchers to visualize cellular and molecular processes effectively. On the other hand, Micro-MRI presents itself as an emerging technology, gaining traction due to its high-resolution imaging capabilities. Micro-MRI provides detailed structural information, which is crucial for understanding complex biological systems. While Optical Imaging is widely adopted across various applications, Micro-MRI is becoming increasingly important in specific research settings, showcasing the evolving landscape of imaging technologies in preclinical research. ### By Reagents: Optical (Largest) vs. MRI Contrast Agents (Fastest-Growing) In the US preclinical imaging market, the market share distribution among the reagents segment showcases Optical reagents as the largest contributing factor, capturing a significant percentage of the overall share. With various applications in imaging and diagnostics, Optical reagents continue to be favored due to their versatility, ease of use, and effectiveness. In contrast, MRI Contrast Agents have emerged as a notable segment, driven by advancements in imaging technologies that enhance diagnostic capabilities. The growth trends within the reagents segment indicate a shift towards more innovative and efficient solutions. The increasing investment in research and development is a primary driver behind the growth of MRI Contrast Agents, which are experiencing a rapid rise in demand due to their expanded applications in various fields. Meanwhile, Optical reagents benefit from a more established presence in the market, yet they continue to evolve with new formulations and techniques that cater to the changing needs of preclinical research. Optical (Dominant) vs. MRI Contrast Agents (Emerging) Optical reagents are recognized as the dominant force within the reagents segment, attributed to their broad applicability across various imaging modalities and robust performance in diagnostic processes. They often provide real-time imaging capabilities, making them a preferred choice in preclinical studies. On the other hand, MRI Contrast Agents are categorized as an emerging segment, characterized by their rapid development and introduction into the market. Advances in formulation technology have enabled these agents to enhance the contrast in MRI scans significantly, promoting their adoption in complex imaging scenarios, thus positioning them as essential tools in enhancing diagnostic accuracy. ## Competitive Benchmarking The [preclinical imaging market](https://www.marketresearchfuture.com/reports/preclinical-imaging-market-7365) is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for innovative imaging solutions. Key players such as Bruker Corporation (US), GE Healthcare (US), and Thermo Fisher Scientific Inc. (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Bruker Corporation (US) focuses on innovation, particularly in developing high-resolution imaging systems that cater to the evolving needs of researchers. Meanwhile, GE Healthcare (US) emphasizes partnerships with academic institutions to foster research and development, thereby enhancing its product offerings. Thermo Fisher Scientific Inc. (US) is strategically investing in digital transformation initiatives, aiming to integrate AI and machine learning into its imaging solutions, which positions it favorably in a competitive environment.The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance market responsiveness. Localizing manufacturing and optimizing supply chains are prevalent strategies, allowing for reduced lead times and improved customer service. The market structure appears moderately fragmented, with several players vying for market share, yet the collective influence of major companies like Siemens Healthineers (DE) and PerkinElmer Inc. (US) contributes to a competitive atmosphere that encourages innovation and collaboration. In September GE Healthcare (US) announced a strategic partnership with a leading biotechnology firm to co-develop advanced imaging technologies aimed at accelerating drug discovery processes. This collaboration is expected to leverage both companies' strengths, potentially leading to groundbreaking advancements in preclinical imaging capabilities. The strategic importance of this partnership lies in its potential to enhance GE Healthcare's product portfolio while addressing the growing demand for efficient drug development solutions. In October Thermo Fisher Scientific Inc. (US) launched a new imaging platform that integrates AI algorithms to improve image analysis and interpretation. This launch signifies a critical step towards enhancing the accuracy and efficiency of preclinical studies. The integration of AI not only streamlines workflows but also positions Thermo Fisher as a leader in the digital transformation of imaging technologies, which is increasingly becoming a competitive differentiator in the market. In August Bruker Corporation (US) expanded its product line by introducing a novel imaging modality that combines MRI and PET technologies. This innovative approach aims to provide comprehensive insights into biological processes, thereby enhancing research capabilities. The strategic importance of this development lies in its potential to attract a broader customer base, particularly in academic and pharmaceutical research settings, where multi-modal imaging is becoming essential. As of November current trends in the preclinical imaging market are heavily influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. Companies that successfully navigate these trends are likely to secure a competitive edge in the rapidly evolving preclinical imaging market. ## Recent News & Developments Recent developments in the US Preclinical Imaging Market have indicated significant advancements and investments in imaging technologies. Companies such as Mediso and Bruker have made strides in enhancing imaging resolutions and capabilities through the development of next-generation imaging systems. PerkinElmer and Thermo Fisher Scientific have also focused on expanding their product portfolios to integrate advanced image analysis software with imaging systems, optimizing research efficiencies. In terms of mergers and acquisitions, a notable transaction occurred in August 2023 when GE Healthcare acquired a leading imaging technology firm, further consolidating its position in the preclinical imaging market. Additionally, Siemens Healthineers has been expanding its portfolio through strategic partnerships aimed at innovating imaging solutions for preclinical research. The growth in valuation for companies within this market segment reflects increasing demand for advanced imaging techniques, facilitating better research outcomes in fields such as drug discovery and development. Over the past few years, significant investments in Research and Development within this sector have propelled advancements in imaging technologies, showcasing an upward trend in market dynamics. ## Report Scope | MARKET SIZE 2024 | 1043.7(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1105.28(USD Million) | | MARKET SIZE 2035 | 1961.2(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Bruker Corporation (US), PerkinElmer Inc. (US), Siemens Healthineers (DE), GE Healthcare (US), Fujifilm Holdings Corporation (JP), Miltenyi Biotec (DE), Thermo Fisher Scientific Inc. (US), Invicro LLC (US), Mediso Medical Imaging Systems (HU) | | Segments Covered | Product, Reagents | | Key Market Opportunities | Advancements in imaging technologies enhance drug discovery and development efficiency in the preclinical imaging market. | | Key Market Dynamics | Technological advancements drive innovation in preclinical imaging, enhancing research capabilities and regulatory compliance. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall valuation of the US preclinical imaging market in 2024?** A: The overall market valuation was $1043.7 Million in 2024. **Q: What is the projected market valuation for the US preclinical imaging market by 2035?** A: The projected valuation for 2035 is $1961.2 Million. **Q: What is the expected CAGR for the US preclinical imaging market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 5.9%. **Q: Which companies are considered key players in the US preclinical imaging market?** A: Key players include Bruker Corporation, PerkinElmer Inc., Siemens Healthineers, GE Healthcare, and others. **Q: What are the main product segments in the US preclinical imaging market?** A: Main product segments include Optical Imaging, Nuclear Imaging, Micro-MRI, Micro-Ultrasound, Micro-CT, and Photoacoustic Imaging Systems. **Q: What were the valuation ranges for Optical Imaging in 2024?** A: The valuation range for Optical Imaging was $150.0 Million to $300.0 Million. **Q: How did the valuation for Nuclear Imaging compare to Micro-CT in 2024?** A: Nuclear Imaging had a valuation range of $200.0 Million to $400.0 Million, similar to Micro-CT, which also ranged from $200.0 Million to $400.0 Million. **Q: What is the valuation range for CT Contrast Agents in the US preclinical imaging market?** A: The valuation range for CT Contrast Agents is $300.0 Million to $600.0 Million. **Q: What is the expected growth trend for the US preclinical imaging market in the coming years?** A: The market is expected to grow steadily, reaching $1961.2 Million by 2035. **Q: What were the valuation figures for Micro-MRI in 2024?** A: The valuation figures for Micro-MRI ranged from $250.0 Million to $500.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-preclinical-imaging-market-13206*